Enhancing Human Milk Production With Domperidone in Mothers of Preterm Infants: Results From the EMPOWER Trial.
Asztalos, Elizabeth V. MD, MSc, FRCPC; Campbell-Yeo, Marsha PhD; da Silva, Orlando P. MD; Ito, Shinya MD; Kiss, Alex PhD; Knoppert, David MScPhm; for the EMPOWER Study Collaborative Group
[Article]
Journal of Human Lactation.
33(1):181-187, February 2017.
(Format: HTML, PDF)
Background: Mothers of preterm infants often are at risk of expressing an inadequate amount of milk for their infants and the use of galactogogues is often considered. Domperidone is a widely used galactogogue with little information available to guide clinicians regarding initiation, timing, and duration of treatment.
Research aim: The primary objective of this study was to determine whether administration of domperidone within the first 21 days after delivery would lead to a higher proportion of mothers achieving a 50% increase in the volume of milk at the end of 14 days of treatment compared with mothers receiving placebo.
Methods: Eligible mothers were randomized to one of two treatment arms: Group A-domperidone 10 mg orally three times daily for 28 days; or Group B-placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days.
Results: A total of 90 mothers of infants <= 29 weeks gestation were randomized. Mean milk volumes at entry were similar for both groups. More mothers achieved a 50% increase in milk volume after 14 days in Group A (77.8%) compared with Group B (57.8%), odds ratio = 2.56, 95% confidence interval [1.02, 6.25], p = .04.
Conclusion: A greater number of mothers experienced a 50% or more increase in human milk volume, but the absolute increase in milk volume was modest.
(C)2017 International Lactation Consultant Association